Monday 16 July 2018

Acute Heart Failure Therapeutics Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.

Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1910

Acute Heart Failure (AHF) Therapeutics Market Drivers

The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.

Various lifestyle factors are responsible to increase risk heart attack and stroke, which includes smoking, overweight, eating foods with high fat and cholesterol, and physical inactivity. Furthermore, patients suffering with heart failure are at high risk to one or more conditions such as coronary artery disease, myocardial infraction, high blood pressure or hypertension, abnormal heart valves, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe lung disease, obesity, and sleep apnea, among others. For instance, according to the World Health Organization (WHO), October 2017 data findings, in 2016, over 1.9 billion adults, were overweight, worldwide. Among which over 650 million were obese. Moreover, according to the same source, raised BMI index, owing to overweight and obesity are the major risk factors for cardiovascular disease, which was the leading cause of death in 2012, worldwide.

Acute Heart Failure (AHF) Therapeutics Market Restraints

Acute heart failure is a common condition associated with considerable morbidity, mortality, and cost. However, evidence-based data on treating heart failure in the acute setting are limited, and current individual treatment options have variable efficacy. Furthermore, healthcare team often need to customize patient care in acute heart failure treatment. For instance, dyspnea is the most common symptom associated with AHF patients. However, this symptom is non-specific as other medical conditions are commonly associated with dyspnea, including pneumonia, exacerbations of chronic obstructive pulmonary disease, pulmonary embolism, acute coronary syndrome, and asthma. This is another factor negatively affecting growth of the acute heart failure (AHF) therapeutics market.

Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis

Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within 5 years of diagnosis.

Furthermore, growing prevalence of obesity have increased risk of developing acute heart failure (AHF). According to CDC, May 2017 data findings, between 2013 and 2014, 37.9% of adults aged 20 years and over were obese, in the U.S. Therefore, high prevalence of risk factors and acute heart failure (AHF) cases in these region are expected to drive growth of this market over the forecast period.

Asia Pacific acute heart failure (AHF) therapeutics market is projected to witness significant growth, due to increasing focus of healthcare organizations in creating awareness regarding increasing risk factors of acute heart failure. For instance, in June 2016, Fortis Hospital, India launched Fortis Heart Rhythm and Heart failure Centre in Bangalore, to increase awareness among people regarding heart failure, stroke, and various other cardiovascular disease.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/acute-heart-failure-ahf-therapeutics-market-1910

Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape

Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.

For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate clinical application in patients.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wednesday 11 July 2018

Human Growth Hormone Market: Drivers, Regional Analysis, and Competitive Landscape 2026

Human body naturally produces growth hormones in the pituitary gland. Human growth hormone is a peptide hormone, which stimulates growth, cell reproduction, and cell regeneration in humans as well as animals. Growth hormone is stored and secreted by somatotropic cells within the lateral wings of anterior pituitary gland. Functions of growth hormones include increased height during childhood, increases calcium retention, strengthens and increases mineralization of the bone, increases muscle mass through sarcomere hypertrophy, promotes lipolysis, increases protein synthesis, stimulates growth of all internal organs excluding the brain, plays a vital role in homeostasis, reduces uptake of glucose by liver, stimulates the immune system, and increases DE iodination of T4 to T3. Excess secretion of growth hormones causes pituitary tumor, which consists of somatotroph cells of the anterior pituitary. These somatotroph cells are benign and grow slowly, producing excess of growth hormones. This causes headaches, impaired vision by pressure caused on optic nerves, deficiency of other hormones secreted by pituitary gland, and thickening the bones of jaw, toes, and fingers, which eventually results in heaviness of jaws and increase in size of digits called as acromegaly. Acromegaly causes pressure on nerves, muscle weakness, and reduced sexual function. The deficiency of growth hormone causes failure in growth, increase in osteoclast activities, weakening of bones, trauma, increase in fat mass, and decrease in muscle mass.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-pdf/1859

Human Growth Hormone Market Drivers:-

Major driver for human growth hormone market is new mergers and acquisitions. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and to bring innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

Robust pipeline is also expected to support the growth in human growth hormone market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults. MOD-4023 sponsored by Opko Biologics, an Israel-based company, completed phase 2 clinical trials in 2015. High prevalence of growth hormone deficiency is another factor boosting growth of human growth hormone market. According to a survey conducted by the National Organization for Rare Diseases (NORA) in 2015, over 10,000 children and 50,000 adults have growth hormone deficiency in the U.S.

However, strict rules and regulations for the use of human growth hormone by athletes and sports professionals is expected to restrain growth of human growth hormone market. The Food and Drug Administration (FDA) and the International Olympic Committee had banned the use of human growth hormone for sports professionals in 2006.

Human Growth Hormone Market Regional Analysis:-

North America is expected to hold dominant position in the global human growth hormone market due to new biosimilar approvals by Health Canada for biosimilar of human growth hormone drugs. For instance, in 2015, Health Canada approved the first generic biological called as PROmnitrope. PROmnitrope is a recombinant human growth hormone used to treat deficiency of growth hormone in adults as well as children. This can encourage new generic version of drugs, thereby fueling the human growth hormone market growth.

Europe human growth hormone market is expected to witness significant growth due to mergers and acquisitions. For instance, in 2017, Ferring Pharmaceuticals S.A., a pharmaceutical company, acquired a product i.e. Zoma Jet of Antares Pharma Inc, a pharmaceutical company. Zoma Jet is a needle free auto injectable device. Ferring Pharmaceuticals S.A acquired Zoma Jet in order to increase use of Zomacton (Injectable somatropin hGH). Zoma Jet is used to deliver Zomacton for the treatment of growth hormone deficiency in children and Turner’s syndrome in girls. By acquiring the injectable device Zoma Jet, would eventually lead to increase in use of the drug, Zomacton, which will further encourage Ferring Pharmaceuticals to develop better treatment options for growth hormone deficiency, thereby resulting in growth of the human growth hormone market. Asia Pacific is expected to grow over the forecast period due to robust pipeline. For instance, Cinna Tropin sponsored by Cinnagen, an Iran-based company, completed phase 3 clinical trials in 2017. This drug is used to treat idiopathic short stature in children and adults.

Click to Continue Reading on Human Growth Hormone Market

Human Growth Hormone Market Key Players:-

Key players operating in the global human growth hormone market include Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

Human Growth Hormone Market Taxonomy:-

By Application
  • Growth Hormone Deficiency
  • Idiopathic short stature
  • Prader-Willi Syndrome
  • Turner Syndrome
  • Others
By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Intramuscular
By Distribution Channel
  • Hospitals
  • Retail Pharmacies
  • Online Pharmacies
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tuesday 10 July 2018

Electric Wheelchair Market: Drivers, Regional Analysis, and Competitive Landscape 2026

An electric wheelchair is a wheelchair that uses electric motor rather than manual power for functioning. Electric wheelchairs are useful for those who cannot use manual wheelchairs or who need to use wheelchairs for considerable long distance. These can be usually used by people who are physically challenged and also senior citizens with problems related to mobility. Design of a wheelchair consists of the following elements: battery, drive system, controller, and seat. The electric motors of these chairs are usually powered by 12-80 ampere per hour of rechargeable deep-cycle batteries. Some users are not able to use hand controllers and therefore, various other options are made available, for instance, sip and puff controllers, which works by blowing into the sensor. Electric wheelchair can also be used by people suffering from diseases such as chronic diseases and asthma. Electric wheelchair offers special features such as tilting capabilities, elevation of seats, and leg elevation. Electric wheelchair can also be dissembled and folded to take it around wherever needed. These are light in weight i.e. less than 100 lbs, and are also compact in size, which is ideal for narrow doorways and small spaces.

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/1758

Electric Wheelchair Market Drivers:-

Growth of the electric wheelchair market is driver by increasing launches of new products with advanced technologies such as automatic folding wheelchair. For instance, in June 2018, Quantum Rehab launched Edge 3, the most advanced power chair, with an upgraded SRS (Smooth Ride Suspension). SRS provides stability, comfortable, and smooth ride. Its standard features include USB charger, drive wheel color accents, and front and rear fender lights. In 2017, Ivacare Corporation, a U.S.-based company, launched TDX-SP2 ELECTRIC WHEELCHAIR. This electric wheel chair has LiNX technology and advanced positioning. LiNX technology electronic system includes wireless programming and remote monitoring, which enables better clinical evaluations and touch screen display. This technology also enables easy intuitive programming and also hassle free functioning of the equipment for its customers. Other factors, which are expected to boost growth of the electric wheelchair market are rising geriatric population, rising awareness related to benefits of use of automated wheelchairs over manual wheelchairs, and increasing prevalence of chronic disorders in geriatric population. According to a survey conducted by Population Reference Bureau in 2016, there were over 46 million senior citizens of the age 65 and above in  U.S. About 48% of this aging population are disabled due to age factor and chronic diseases. According to a survey conducted by the U.S. Census Bureau in 2017, around 40 million people in the U.S. are physically challenged. Moreover, according to a survey conducted by Center for Disease Control and Prevention in 2016, over 117 million people were diagnosed with chronic disorders. All these factors are expected to support growth of the electric wheelchair market over the forecast period (2018-2026).

Electric Wheelchair Market Regional Analysis:-

North America is expected to hold dominant position in the global electric wheelchair market, and is also expected to exhibit a significant growth rate, owing to increasing launches of novel products in the market. For instance, in April 2018, Quantum Rehab, a U.S.-based company, launched Kozmo and Kozmo Portable. This device is especially made for children. The size of Kozmo Portable electric wheelchair is compact and easy to carry. It helps in fast transport and is convenient for parents and children. Moreover, in April 2018, Quantum Rehab launched products including TRU-BALANCE 3 and TRU- BALANCE FLEX. Such new range of products is expected to fuel growth of the electric wheelchair market. Furthermore, Medicare, national (U.S.) health insurance program provides reimbursements on buying an electric wheel chair. The patient pays 20% of the amount mentioned for a given product and Medicare pays the remaining 80%. Such reimbursement plans can boost adoption of the electric wheel chair market in North America.

Click to Continue Reading on Electric Wheelchair Market

Asia Pacific is also expected to witness high growth in the global electric wheel chair market, due to rise of chronic diseases in geriatric population and increasing launch of electric wheel chairs with advanced technology. According to a survey conducted by National Institutes of health in 2015, cardiovascular disease is rising in Asian population. Cardiovascular disease has caused approximately 52% of deaths in India.  For instance, in 2017, Whill Inc., a Japan-based company, launched Model M. This device has omni-wheel technology, which can be used on rough terrain. It also has a compact size and its agile steering can easily navigate in narrow and tight spaces. Such innovations are expected to fuel growth of the electric wheelchair market.

Electric Wheelchair Market Key Players:-

Key players are operating in the electric wheelchair market are Drive Medical Ltd., Permobil AB, Quantum Rehab, GF Health Products Inc., Invacare Corporation, Karman Healthcare, Pride Mobility Products Corp, LEVO Ag, MEYRA GmbH, OttoBock Healthcare GmbH, Whill Inc., and Sunrise Medical Limited.

Electric Wheelchair Market Taxonomy:- 

By Product Type:-
  • Rear Wheel Drive
  • Front Wheel Drive
  • Center Wheel Drive
  • Standing Electric Wheelchair
By End Users:-
  • Home Care Settings
  • Hospitals/ Clinics
  • Others
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday 9 July 2018

Picture Archiving and Communication System Market to Reach Beyond US$ 3 Billion by 2025

The Global Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.7 billion in 2017 and is projected to exhibit a CAGR of 5.5% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights. The Picture Archiving and Communication System (PACS) market is expected to gain significant traction, due to increasing demand for healthcare IT platforms.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1872

Increasing demand for healthcare IT is expected to drive growth of the market

Improvements in the healthcare IT field, such as the introduction of PACS and cloud computing have provided a new prospect to the healthcare providers and hospital to improve patient centricity by boosting operational efficiencies. Various government initiatives to promote electronic data sharing and EHR adoption will allow healthcare providers to improve the clinical outcomes, with streamlining workflow. In 2009, Health Information Technology for Economic and Clinical Health (HITECH) Act, has provided over US$ 35billion incentives to expand and encourage the adoption and use of EHRs by health care professionals and hospitals. Moreover, increase in the competition among hospitals has made it necessary for management to take appropriate measures increase their efficiency with the integration of these systems at all levels.

Furthermore, the rapidly mounting geriatric population base is demanding healthcare information systems such as PACS to meet the medical requirements. According to a NIH report, in 2015, 8.5% of people were aged 65 and over. This percentage is expected to reach around 17% of the world’s population by 2050. Moreover, healthcare IT companies are continuously funding the development of new and advanced solutions. The advent of these solutions is, thus, providing growth opportunities in PACS market.

Key players are focusing on new product launches and improvements in existing ones in order to accelerate business growth. For instance, in June, 2015, Ricoh India, a leader in the field of Imaging Solutions, launched its fully integrated cloud-enabled PACS solution ‘Picasso’. This new solution will provide access of medical images to clinicians and patients, along with reducing the cost of providing medical care. In 2017, FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics products, launched version 5 of Synapse PACS in the U.S. Synapse 5 is one component of Fujifilm’s comprehensive enterprise imaging portfolio which includes RIS, 3D, Cardiovascular, Enterprise Viewer, Synapse VNA, and cloud services.

Browse 39 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Imaging Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026”

To know the latest trends and insights prevalent in the Picture Archiving and Communication System (PACS) market, click the link below: https://www.coherentmarketinsights.com/market-insight/picture-archiving-and-communication-system-pacs-market-1872

Key Takeaways of the Picture Archiving and Communication System (PACS) Market:
  • The global picture archiving and communication system (PACS) market is expected to exhibit a CAGR of 5.5% over the forecast period, owing to increasing adoption of health IT among healthcare providers.
  • Among deployment, the cloud based segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to more imaging modalities demanding cloud-based PACS.
  • Among product, the mid end PACS segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increase in adoption rate and growing demand for integrated solutions Among end user, hospitals segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increased usage in hospitals for imaging.
  • North America picture archiving and communication system (PACS) market is expected to exhibit significant growth, owing to large number of hospitals and imaging centers using imaging techniques.
  • Key players operating in the global picture archiving and communication system (PACS) market include Agfa-Gevaert Group, Carestream Health, FUJIFILM Medical Systems, INFINITT Healthcare Co. Ltd., GE Healthcare, Koninklijke Philips N.V., Merge Healthcare Solutions Inc., Mckesson Corp., Sectra AB and Siemens Healthineers.
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Wednesday 4 July 2018

Specialty Injectable Generics Market Clinical Review, Drug Descriptions, Analysis and Synthesis 2026

Specialty injections are high cost medications or drugs that are used to treat various complex diseases such as cancer, HIV, rheumatoid arthritis, hemophilia, and central nervous system diseases. Specialty injections are often biologics that are produced by biotechnology methods. Specialty drugs are complex to manufacture. Some specialty injectable can be self-administered.

Specialty drugs may also be defined as orphan or ultra-orphan drugs under the U.S. Orphan drug act 1983. This was enacted to facilitate development of orphan drugs, which are drugs for rare diseases such as Huntington’s disease, muscular dystrophy, amyotrophic lateral sclerosis, and myoclonus.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1877

Specialty Injectable Generics Market Drivers:

New product launches are expected to be a major driver for growth of the specialty injectable generics market. For instance, in 2015, Avatis Plc., a global specialty pharmaceutical company, launched specialty generic injections portfolio. This portfolio includes generic versions of Gemzar, Campostar, Taxotere, and Zometa, which are used for the treatment of cancer.

In 2016, Teva Pharmaceuticals Industries Ltd. launched generic equivalent to Imitrex 1 (sumatriptan) injection, 4mg and 6mg single-dose. Sumatriptan is used in the treatment of acute migraines and acute cluster headaches in adults. Sumatriptan injection can be self-administered subcutaneously into the outer thigh or an arm.

Mergers and acquisitions are also expected to boost growth of the specialty injectable generics market size. For instance, in 2014, Sagent Pharmaceuticals Inc., a specialty pharmaceutical company, acquired Omega Laboratories Ltd., a specialty pharmaceutical company, to develop and enhance their specialty injectable portfolio.

In 2015, Endo International Plc., a generic and specialty pharmaceutical company, acquired Par pharmaceutical companies Inc., which markets, develops, and distributes generic drugs in the U.S., to develop and enhance its generic injectable drugs portfolio and to double the revenue generated by its generic division.

Prevalence of diseases such as cancer, central nervous system disorders, and chronic diseases are also expected to drive the specialty injectable generics market growth. According to a survey conducted by the National Institute of Health in 2018, there are over 23,880 new cancer cases in the U.S.


Restraints of specialty injectable generics market include high cost of medications, which is required over a long period of time. For instance, 1g Gemzar (gemcitabine) indicated for the treatment costs around US$ 800 in the U.S. and the price varies with region. Therefore, high cost of medications severely limits the adoption rate.

Specialty Injectable Generics Market Regional Analysis:

North America is expected to hold dominant position in the global specialty injectable generics market due to mergers and acquisitions. For instance, in May 2018, Impax Laboratories Inc. partnered with Amneal Pharmaceuticals Inc., a specialty pharmaceutical company to develop affordable and more accessible specialty injectable generics. This will lead to the development of new injectable generics for the treatment of various diseases.

New product launches are also expected to boost North America specialty injectable generics market growth. In March 2018, Teva pharmaceutical Industries Ltd. launched generic version of Aloxi injection 0.25mg/5ml called as Palonosetron hydrochloride injection in the U.S. market.

Europe is expected to witness growth owing to rising number of cancer patients. According to a study conducted by the World Health Organization (WHO) in 2016, over 753,600 people were diagnosed with cancer in this region.

Asia Pacific specialty injectable generics market is expected to witness significant growth over the forecast period owing to new product launches. For instance, in June 2018, Dr. Reddy’s Laboratories, an Indian pharmaceutical company, launched specialty generic injection Levetiracetram in sodium chloride injection, which is a generic version of HQ Specialty Pharma Corporation’s Levetiracetram in sodium chloride injection.

Mergers and acquisitions is also expected to fuel growth of the market in this region. In 2017, Lupin Ltd. acquired Symbiomix Therapeutics LLC., a pharmaceutical company, to develop and expand in women health segment.

Specialty Injectable Generics Market Key Players:

Key players operating in this market include Pfizer Inc., Mylan N.V., Teva Pharmaceuticals Industries Ltd., Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals Plc. New product launches by key players is expected to drive the specialty injectable generics market growth. For instance, in 2017, Mylan N.V., a global generic and specialty pharmaceuticals company, launched the generic version of Pfizer’s Cerebryx, which is an injectable variety of fasphenytoin sodium.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Monday 2 July 2018

Human Recombinant Insulin Market to surpass US$ 47.8 billion by 2026: CMI

The Global Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued US$ 27.4 billion in 2018, and is projected to exhibit a CAGR of 7.2% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.

Browse 35 Market Data Tables and 42 Figures spread through 205 Pages and in-depth TOC on "Human Recombinant Insulin Market, by Product Type (Rapid-Acting Human Insulin, Short-Acting Human Insulin, Intermediate-Acting Human Insulin, Long-Acting Human Insulin, and Premixed Human Insulin), by Brand (Humalog, Novolog, Apidra, Humulin R, Novolin R, Humulin N, Novolin N, Levemir, Lantus, Humalog Mix, Novolog Mix, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"

To know the latest trends and insights related to human recombinant insulin market, click the link below: https://www.coherentmarketinsights.com/market-insight/human-recombinant-insulin-market-1797

Key manufacturers are engaged in launching novel human insulin portfolio and gaining regulatory approval for their insulin product portfolio. For instance, in August 2014, Eli Lilly and Company launched Jardiance (empagliflozin) as a treatment option for Type 2 diabetes patients in the U.S. Jardiance is a sodium glucose co-transporter-2 (SGLT2) inhibitor with Type 2 diabetes patients. In March 2016, Biocon Limited collaborated with LaboratoriosPiSA S.A de CV (PiSA) to jointly develop and sell a generic recombinant human insulin in America. Biocon expects the product to launch by 2020 in the U.S. In February 2018, Novo Nordisk launched Fiaspa: a fast-acting mealtime insulin in the U.S. Fiaspa received U.S. FDA approval and indicated to improve glycemic control in adults with type 1 and type 2 diabetes. In December 2017, the U.S. Food and Drug Administration (FDA) approved Sanofi’s Admelog. Admelog is a follow-on mealtime insulin, which helps people living with diabetes manage blood sugar levels at mealtime.

Efficient diabetes management and ease of use creates need for advancements in current solutions of both insulin and its delivery systems thereby, offering reduced patient discomfort. Glucose Responsive Insulin (GRI) or smart insulin is a novel technology for people with diabetes, which works by automatically reacting to blood sugar fluctuations in body and responds to changing blood glucose levels. The lower or higher blood sugar levels are lead to release of more or less insulin, respectively. Smart insulin decreases the number of regular blood tests required and also minimizes the number of daily dose of insulin injections. Researchers from the University of North Carolina have been working on a smart insulin patch. For instance, in 2015, researchers reported that, smart insulin patch can use a micro-needles system to automatically detect high blood glucose levels and administer insulin appropriately.

To get holistic SAMPLE of the report including table of contents: https://www.coherentmarketinsights.com/insight/request-sample/1797

Key players in the human recombinant insulin market are implementing inorganic growth strategies to develop and introduce smart insulin technology in the market. For instance, in February 2016, Eli Lilly and Company acquired Glycostasis, Inc., a startup company engaged in developing smart insulin. Eli Lilly and Company is focused on developing Glycostasis’s ‘smart insulin’ technology.

Key takeaways of the Human Recombinant Insulin Market:
  • The global human recombinant insulin market is expected to expand at a CAGR of 7.2% during the forecast period (2018 – 2026), owing to increasing technological advancement in recombinant human insulin by various key players.
  • Long acting human insulin are projected to grow with higher pace during the forecasted period in the product type segment, owing to their higher efficiency and ability to offer consistent insulin delivery throughout the day, lasting 24 hours.
  • Other brands hold major market share in brand segment, due to the involvement of innovative and new human recombinant insulin portfolio with increased patent expiry period such as Toujeo, Tresiba, Basaglar, among others; in this segment, which further expected to capture higher market share, during the forecast period.
  • Retail pharmacies holds largest market share in distribution channel segment. As retail pharmacies offer direct access to full range of diabetes products, covering all prescription and over-the-counter products for patients with diabetes.
  • Some of the major players operating in global human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.
About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.